Skip to content

Optimization of clinical solutions for Helicobacter pylori-resistant patients

Optimization of clinical solutions for Helicobacter pylori-resistant patients: Single-center, prospective study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020009
Enrollment
Unknown
Registered
2018-12-11
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Group 1:Full-length sequencing of Hp, simultaneous gastric micro-ecological monitoring
Group 2:Hp in vitro susceptibility test, simultaneous gastric microecology test
Group 3:simultaneous gastric microecology test

Sponsors

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients who have failed to eradicate Helicobacter pylori 2 or more times according to the fifth Chinese Helicobacter pylori diagnosis and treatment guidelines; (2) The criterion for Helicobacter pylori positive is positive for breath test and/or pathologically positive; (3) Aged 18-65 years old male and female; (4) Voluntarily accept the test and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients who have used antibiotics, expectorants, and proton pump inhibitors in the past 1 month; history of major gastrectomy; severe complications such as upper gastrointestinal bleeding and pyloric obstruction; (2) Those with serious primary diseases such as cardiovascular, cerebrovascular, liver and kidney, hematopoietic system, hyperthyroidism, diabetes, etc., or serious diseases (such as tumors) and mental patients that affect their survival; (3) allergic diseases; (4) Pregnancy, or preparation for pregnancy, lactating women; (5) cognitive dysfunction cannot give sufficient informed consent; (6) The investigator believes that there are patients who are not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Hp full-length gene sequencing;in vitro antimicrobial susceptibility testing;Stomach microecology;Hp serological typing;Pathological HE/GIEMSA staining;

Countries

China

Contacts

Public ContactLin Rong

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Selinalin35@hotmail.com+86 15971426638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026